The searchable Abstract lists are here .
I am hoping for some decent data on the anti PD1 PLUS combinations to prevent acquired resistance in the immunotherapies and also some strategies to improve the durability of Targeted Therapies.
I also hope we have some better REAL WORLD data that will enrich what we have from the Clinical trials on optimal sequencing of therapies, identification and management of side effects and the most useful imaging and diagnostics to predict response and progression. It is also also worth spending time learning from the other disease areas that use the same drug classes as us, to see what we can share from their experience.

Who benefits from adjuvant Dab/ Tram therapy? EVERYONE.
ReplyDeletehttps://meetinglibrary.asco.org/record/174893/abstract
Brain mets are different from skin primaries with some interesting findings to think through.
ReplyDeletehttps://meetinglibrary.asco.org/record/174859/abstract